News & Events about Acumen Pharmaceuticals Inc.
TipRanks Financial Blog
6 months ago
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals (ABOS Research Report), with a price t... In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals (ABOS –...
Acumen Pharmaceuticals (NASDAQ:ABOS Get Rating) and Elevation Oncology (NASDAQ:ELEV Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, ...
Globe Newswire
7 months ago
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing a novel ...
HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS Get Rating) in a report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. ABOS has been the subject of a number of other research reports. ...
Globe Newswire
9 months ago
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease (AD), today announced Derrell ...